EU approves Adtralza for moderate-to-severe atopic dermatitis – LEO Pharma
LEO Pharma announced that the European Commission (EC) has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy…. read more.